














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Abia	 4	 340	 1	 899	 11,669	
Adamawa	 4	 16	 4	 896	 15,873	
Akwa	Ibom	 4	 340	 2	 923	 37,997	
Anambra	 5	 304	 1	 1,181	 36,632	
Bauchi	 4	 40	 3	 898	 34,057	
Bayelsa	 4	 86	 2	 900	 5,765	
Benue	 5	 445	 4	 1,172	 276,377	
Borno	 4	 4	 1	 899	 3,973	
Cross	River	 4	 432	 3	 900	 25,188	
Delta	 4	 48	 2	 898	 45,426	
Ebonyi	 4	 163	 3	 900	 75,121	
Edo	 4	 36	 3	 812	 17,295	
Ekiti	 4	 30	 1	 900	 11,270	
Enugu	 5	 266	 4	 954	 71,717	
FCT	 5	 214	 4	 1,199	 100,090	
Gombe	 4	 188	 3	 900	 107,230	
Imo	 4	 285	 1	 898	 94,290	
Jigawa	 4	 32	 3	 900	 43,921	
Kaduna	 5	 422	 4	 1,190	 350,494	
Kano	 5	 270	 5	 1,200	 185,368	
Katsina	 4	 15	 4	 900	 32,988	
Kebbi	 4	 27	 4	 900	 30,761	
Kogi	 4	 198	 2	 900	 53,766	
Kwara	 4	 27	 2	 871	 28,251	
Lagos	 7	 267	 2	 1,650	 55,120	
Nasarawa	 4	 180	 4	 895	 74,786	
Niger	 4	 112	 2	 900	 66,248	
Ogun	 4	 44	 3	 900	 27,122	
Ondo	 4	 52	 4	 900	 37,143	
Osun	 4	 25	 0	 900	 11,781	
Oyo	 5	 170	 2	 1,200	 91,230	
Plateau	 4	 230	 3	 890	 78,838	
Rivers	 5	 264	 3	 1,323	 25,929	
Sokoto	 4	 10	 3	 900	 20,562	
Taraba	 4	 55	 1	 896	 8,930	
Yobe	 5	 5	 1	 1,200	 12,003	
Zamfara	 4	 20	 1	 887	 31,844	
State	Average	(Mean)	4	 153	 3	 985	 60,461	
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Mean ([ANC Sentinel Surveilance + PMTCT Program Data]/2)
Solid black lines are mean & +/- 2 SDs; dashed line is the 0 line
ANC Sentinel Surveilance Prevalence (2014) vs PMTCT Program Prevalence (2015) in Nigeria























Abia	 17	 340	 11,669	 2.9%	
Adamawa	 13	 16	 15,873	 2.6%	
Akwa	Ibom	 31	 340	 37,997	 6.8%	
Anambra	 21	 304	 36,632	 3.7%	
Bauchi	 15	 40	 34,057	 1.3%	
Bayelsa	 8	 86	 5,765	 3.1%	
Benue	 23	 445	 276,377	 4.4%	
Borno	 4	 4	 3,973	 2.5%	
Cross	River	 18	 432	 25,188	 2.8%	
Delta	 24	 48	 45,426	 3.6%	
Ebonyi	 13	 163	 75,121	 1.2%	
Edo	 15	 36	 17,295	 4.0%	
Ekiti	 16	 30	 11,270	 2.1%	
Enugu	 17	 266	 71,717	 2.1%	
FCT	 6	 214	 100,090	 3.1%	
Gombe	 11	 188	 107,230	 1.1%	
Imo	 27	 285	 94,290	 1.7%	
Jigawa	 14	 32	 43,921	 0.5%	
Kaduna	 23	 422	 350,494	 1.3%	
Kano	 38	 270	 185,368	 0.5%	
Katsina	 11	 15	 32,988	 0.9%	
Kebbi	 12	 27	 30,761	 0.6%	
Kogi	 20	 198	 53,766	 2.3%	
Kwara	 8	 27	 28,251	 2.1%	
Lagos	 20	 267	 55,120	 2.7%	
Nasarawa	 13	 180	 74,786	 4.5%	
Niger	 24	 112	 66,248	 1.7%	
Ogun	 16	 44	 27,122	 3.0%	
Ondo	 18	 52	 37,143	 2.5%	
Osun	 12	 25	 11,781	 2.1%	
Oyo	 33	 170	 91,230	 1.4%	
Plateau	 17	 230	 78,838	 2.4%	
Rivers	 23	 264	 25,929	 3.7%	
Sokoto	 7	 10	 20,562	 1.0%	
Taraba	 15	 55	 8,930	 5.7%	
Yobe	 5	 5	 12,003	 0.8%	
Zamfara	 8	 20	 31,844	 0.6%	
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	 n	 Prop.	 Prop.	 Prop.	
Level	1	(individual-level)	outcomes	 	 	 	 	
Positive	infant	HIV	status	(positive	
DNA-PCR	result	at	6	weeks	
postpartum)	(n=3,458)	 163	 0.05	 0.05	 0.05	
Mother	was	on	ART	during	
pregnancy	(n=3,473)	 3,046	 0.89	 0.81	 0.88	
Level	2	(facility-level)	variables	 	 	 	 	
Average	monthly	patient	volume	
(n=3,489)	 	 	 	 	
		<100		 762	 0.19	 0.33	 0.22	
		100-199		 1,241	 0.37	 0.31	 0.36	
		200-299		 683	 0.20	 0.16	 0.20	
		300-399		 419	 0.11	 0.14	 0.12	




		<10		 1,435	 0.39	 0.50	 0.41	
		10-19	 665	 0.20	 0.15	 0.19	
		20-29	 566	 0.17	 0.14	 0.16	
		30-39	 316	 0.08	 0.13	 0.09	
		40+		 507	 0.16	 0.08	 0.15	
Average	monthly	ratio	of	newly	
identified	HIV+	patients	to	known	
HIV+	positive	(n=3,489)	 	 	 	 	
		Mean,	(std	dev)	 3,489	 1.18,	(0.66)	 1.19,	(0.69)	 1.18,	(0.67)	
Study	site	is	public	sector	facility	
(compared	to	mission	/	faith-based)	
(n=3,489)	 2,949	 0.87	 0.74	 0.85	
	 70	
Study	site	is	urban,	boma	(peri-
urban),	or	rural	(n=3,489)	 	 	 	 	
		Urban		 1,242	 0.35	 0.38	 0.36	
		Boma	(peri-urban)		 499	 0.16	 0.10	 0.14	









			Mean,	(std	dev)	 3,489	 0.81,	(0.12)	 0.70,	(0.16)	 0.79,	(0.14)	
Level	1	(individual-level)	variables	 	 	 	 	
Time	spent	traveling	to	the	clinic	
from	home	(n=3,390)	 	 	 	 	
		<1	hour		 1,546	 0.46	 0.44	 0.46	
		1-2	hours	 1,274	 0.38	 0.36	 0.38	
		>2	hours		 570	 0.16	 0.20	 0.17	
Parity:	third	or	greater	child	
(n=3,489)	 1,149	 0.32	 0.37	 0.33	
Child	was	born	in	a	health	facility	
(n=3,401)	 3,224	 0.95	 0.95	 0.95	




























































Level	2	(facility-level)	variables	 	 	 	 	
Average	monthly	patient	volume	(ref:	<100)	 	 	 	 	
			100-199	 1.01	 0.98	 0.36	 2.81	
			200-299	 1.86	 0.16	 0.79	 4.42	
			300-399	 2.52	 0.01	 1.31	 4.84	
			400+	 1.38	 0.32	 0.73	 2.62	
Average	monthly	HIV	positive	patient	volume	(ref:	<10)	 	 	 	 	
			10-19	 1.43	 0.56	 0.43	 4.72	
			20-29	 1.44	 0.39	 0.63	 3.28	
			30-39	 1.57	 0.04	 1.01	 2.43	
			40+	 2.24	 0.04	 1.04	 4.82	
Ratio	of	newly	identified	to	known	positive	patients	 1.25	 0.08	 0.97	 1.61	
Clinic	is	urban,	boma	(peri-urban),	or	rural	(ref:	urban)	 	 	 	 	
			Boma	(peri-urban)	 1.41	 0.46	 0.57	 3.49	
			Rural		 0.61	 0.00	 0.46	 0.80	
Nurse	&	doctor	to	patient	ratio	 1.04	 0.93	 0.43	 2.50	
Site	is	public	facility	(ref.:	faith-based)	 3.73	 <0.01	 1.67	 8.32	
Average	proportion	of	mothers	at	the	study	site	attending	
al	ANC,	PNC,	and	wel	child	visits	at	the	same	site		
1.09	 0.93	 0.14	 8.66	
Level	1	(individual-level)	variables	 	 	 	 	
Mother	attended	same	site	for	ANC,	PNC,	&	wel	child	care		 0.78	 0.51	 0.38	 1.63	
Travel	time	to	clinic	(ref.:	<1	hour)	 	 	 	 	
			1-2	hours		 0.95	 0.79	 0.65	 1.38	
			>2	hours		 0.90	 0.82	 0.35	 2.27	







	+)	 2.06	 0.03	 1.09	 3.87	


























































Variable	 OR	(95%	CI)	 p	 OR	(95%	CI)	 p	
Level	2	(facility-level)	variables	 	 	 	 	
Ratio	of	newly	identified	to	
known	positive	patients	
1.20	(0.96,	1.51)	 0.11	 1.93	(1.49,	2.50)	 <0.01	
Nurse	&	doctor	to	patient	ratio	 0.31	(0.07,	1.37)	 0.12	 3.87	(1.40,	10.73)	 0.01	
Site	is	public	facility	(ref.:	faith-
based)	
4.57	(1.16,	18.02)	 0.03	 2.51	(0.95,	6.64)	 0.06	
Level	1	(individual-level)	variables	 	 	 	 	
Travel	time	to	clinic	(ref.:	<1	hour)		 	 	 	
			1-2	hours		 0.89	(0.52,	1.51)	 0.65	 1.79	(0.93,	3.43)	 0.08	
			>2	hours		 0.84	(0.38,	1.88)	 0.67	 	2.38	(0.31,	18.18)	 0.40	
Mother	delivered	child	in	health	
facility	









1.71	(0.64,	4.59)	 0.29	 2.73	(1.47,	5.05)	 <0.01	
Random	Efects	 	 	 	 	
		Variance	at	district	level	 0.35	(0.09,	1.34)	 	 0.23	(0.08,	0.69)	 	
		Variance	at	facility	level	 0.34	(0.11,	1.04)	 	 <0.01	(<0.01,	<0.01)	 	



























Level	2	(facility-level)	variables	 	 	 	 	
Average	monthly	patient	volume	(ref:	<100)	 	 	 	 	
			100-199	 0.86	 0.57	 0.51	 1.45	
			200-299	 0.82	 0.43	 0.51	 1.33	
			300-399	 0.62	 0.41	 0.20	 1,94	
			400+	 0.35	 <0.01	 0.24	 0.51	
Average	monthly	HIV	positive	patient	volume	(ref:	<10)	 	 	 	 	
			10-19	 0.75	 0.38	 0.39	 1.44	
			20-29	 0.76	 0.39	 0.41	 1.41	
			30-39	 0.29	 <0.01	 0.23	 0.34	
			40+	 0.59	 0.13	 0.30	 1.17	
Ratio	of	newly	identified	to	known	positive	patients	 1.18	 0.25	 0.89	 1.55	
Clinic	is	urban,	boma	(peri-urban),	or	rural	(ref:	urban)	 	 	 	 	
			Boma	(peri-urban)	 1.59	 0.02	 1.08	 2.34	
			Rural		 1.98	 <0.01	 1.56	 2.52	
Nurse	&	doctor	to	patient	ratio	 1.49	 0.23	 0.77	 2.88	
Site	is	public	facility	(ref.:	faith-based)	 0.32	 <0.01	 0.15	 0.70	
Average	proportion	of	mothers	at	the	study	site	attending	
al	ANC,	PNC,	and	wel	child	visits	at	the	same	site		
1.30	 0.60	 0.48	 3.54	
Level	1	(individual-level)	variables	 	 	 	 	
Mother	attended	same	site	for	ANC,	PNC,	&	wel	child	care	 2.26	 <0.01	 1.59	 3.23	
Travel	time	to	clinic	(ref.:	<1	hour)	 	 	 	 	
	 77	
			1-2	hours		 1.15	 0.53	 0.74	 1.80	
			>2	hours		 1.76	 0.06	 0.99	 3.13	







	+)	 0.38	 <0.01	 0.28	 0.52	

























































Variable	 OR	(95%	CI)	 p	 OR	(95%	CI)	 p	
Level	2	(facility-level)	variables	 	 	 	 	
Ratio	of	newly	identified	to	
known	positive	patients	
2.03	(1.41,	2.92)	 <0.01	 0.75	(0.58,	0.96)	 0.02	
Nurse	&	doctor	to	patient	ratio	 2.78	(1.71,	4.50)	 <0.01	 0.91	(0.59,	1.43)	 0.69	
Site	is	public	facility	(ref.:	faith-
based)	
0.47	(0.24,	0.92)	 0.03	 0.44	(0.26,	0.76)	 <0.01	
Level	1	(individual-level)	variables	 	 	 	 	
Travel	time	to	clinic	(ref.:	<1	
hour)	 	 	 	 	
			1-2	hours		 1.14	(0.74,	1.74)	 0.56	 0.96	(0.35,	2.62)	 0.93	
			>2	hours		 2.74	(1.25,	6.00)	 0.01	 0.85	(0.35,	2.10)	 0.73	
Mother	delivered	child	in	health	
facility	









1.02	(0.47,	2.21)	 0.96	 0.41	(0.20,	0.83)	 0.01	
Random	Efects	 	 	 	 	
		Variance	at	district	level	 0.35	(0.16,	0.74)	 	 0.43	(0.09,	1.97)	 	
		Variance	at	facility	level	 0.26	(0.10,	0.71)	 	 			<0.01	(<0.01,	1.35E+14)	
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1 The term “Mother-Infant Pair” is inclusive of any woman who is not the biological mother of an HIV-
exposed child, but who has an HIV-exposed child in their care and who wil be folowed with the child for 














































































































































































































































































                        
2 This ELISA confirmation is at MOH request, as validation of rapid HIV testing in high-burden ANC 































































































































































                        
3 Please note these definitions are specific to this study and not the same as the National HIV Guidelines; 





























































































	 	•Al infants 4-26 weeks of age presenting at under-5 
clinics using DBS for ELISA and DNA-PCR 
confirmation 
 
•Al mothers/caregivers of infants (above) using 





•3,376 Mother-infant pairs of which 1,448 infants 
are 4-12 weeks of age for annual 24 month folow 
up 
 
•Identify as a subset of 1,324 mother-infant pairs 
for annual 48 month folow up, of which 500 wil 
be folowed quarterly 
Infants 6-12 weeks: 
•Early transmission 
•HIV prevalence at first vaccination visit 
Children 12 and 24 months: 
•Transmission 
•HIV-free survival 
•ART initiation, retention and adherence 
48 month extended folow up: 
•Long-term retention in ART 
•Virological and clinical outcomes 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































X	X		 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Development	of	electronic	
data	entry	
	 X	X	X		 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Pilot	study	 	 X	X		 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Revision	of	tools/data	entry	
system	
	 	 X	X		 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Selection	of	lay	workers/	
supervisors	
	 X	X	X		 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Training	of	study/	program	
staf	
	 	 X	X		 	 	 	 	 	 	 	 	 	 	 X		 	 X		 X		 	
Data	colection/	entry	 	 	 	 	 X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	X	
Data	cleaning	and	analysis	 	 	 	 	 	 	 X		 	 X		 	 X		 	 X		 X	X	X	X	X	X	














































































































1	 N/CW/CE	 20	 3,942	 46	 20	 3	 1	
2	 Lilongwe	 13	 4,008	 63	 30	 3	 1	
3	 SW/SE	 22	 13,395	 42	 18	 4	 2	




































































N % N % N % N %
National   640,576 8.4% 10.4% 97%  66,880  64,874 77%  34,062 50.9% 32,818 50.6% 11,790 36% 21,028 64%
Strata
North, Central W & E Rural 245,378  5.0% 6.3% 97%  15,428  14,965 72%  7,736 50.1%  7,692 51.4%  3,808 39%  3,884 61%
Lilongw e 86,634  6.2% 7.8% 97%  6,725   6,523 83%  2,583 38.4%  4,142 63.5%  1,572 30%  2,570 70%
South W & E Rural 267,028  11.3% 14.1% 97%  37,684  36,554 77%  18,586 49.3% 19,098 52.2%  7,532 36% 11,566 64%
Blanty re 41,536  10.9% 13.6% 97%  5,649   5,479 75%  1,453 25.7%  4,196 76.6%  2,080 37%  2,116 63%
640,576  65,486 63,522 35,128 14,992 20,136 
Population	Denominator	(not	Program) 	PMTCT	Cascade	Coverage	




 ART in ANC 
 ART before 
preg 


























































N % N % N %
National  8,453 13.0% 12,377 19.1% 17,291 26.7%2.5%2.0 1,376 2,363 30% 1,448 3,376 
Strata
North, Central W & E Rural  1,895 12.7%  2,788 18.6%  3,904 26.1%5.0%1.5 253  436  30% 266   623   399  917  14,585   
Lilongw e  687 10.5%  1,048 16.1%  1,494 22.9%5.0%1.5 250  391  30% 263   559   394  822  10,594   
South W & E Rural  4,627 12.7%  6,809 18.6%  9,537 26.1%5.0%1.5 253  441  30% 266   630   399  928  6,572    
Blanty re  425 7.8%    697 12.7%  1,025 18.7%5.0%1.5 163  337  30% 172   481   257  709  5,212    
7,634 12.0%11,342 17.9%15,960 25.1% 919  1,605 967   2,293 1,448 3,376 36,963  















 MTCT at 24 
mos 
Estimated	transmission	rates
 MTCT at 4-12 
w eeks 
 MTCT at 12 
mos* 
Continued 
from 
previous 
page 
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NEMAPP	Appendix	3.	Description	48	Months	Extended	Folow	Up	
	
Summary:	The	48	months	extended	cohort	wil	alow	the	study	team	to	folow	a	subset	
of	1,324	mother-infant	pairs	annualy	to	48	month	post-partum	to	determine	survival,	
standardized	ART	outcomes,	and	enhanced	clinical	outcomes	(including	blood	sampling	
for	CD4,	viral	load	and	hepatitis	screening/disease	specific	markers).	In	a	smaler	subset	
of	500	mother-infant	pairs	(out	of	the	1,324),	enhanced	folow	up	for	more	detailed	
description	of	morbidity,	growth,	adverse	efects	and	drug	toxicity,	recurrent	
pregnancies	and	family	planning	utilization	wil	be	done	through	quarterly	study	visits.			
	
Objectives:		
1.	Estimate	long-term	survival	at	12,	24,	36	and	48	months	for	mother-infant	pairs	
initiated	on	ART	under	Option	B	Plus	and	describe	maternal	and	infant	characteristics	
associated	with	mortality.	
2.	Measure	rates	of	long-term	retention	in	ART	for	HIV-infected	mothers	and	their	
infants	to	48	months	(alive	on	ART,	defaulted,	stop	ART,	transferred;	including	
intercurrent	changes	of	the	defaulted	and	stop	ART	status)	
3a.	Estimate	long-term	ART	adherence	via	routinely	colected	data	(pil	counts,	missed	
pil	self-reports	and	missed/delayed	visits	from	standard	maternal	ART	cards)	and	
enhanced	study	visit	screening	(via	quarterly	questionnaire)		
3b.	Estimate	long-term	adherence	and	ART	failure	by	viral	load	measurement	colected	
at	6,	12,	24,	36	and	48	months	post	ART	initiation.	Describe	the	maternal	characteristics	
that	are	associated	with	non-adherence	and	ART	failure.	
4.	Describe	immunological	and	clinical	outcomes	among	mother-infant	pairs,	including	
co-morbid	conditions,	hospitalizations,	opportunistic	infections	(including	TB	
screening/case	finding)	and	biometric	measurements	(growth,	BMI)	at	quarterly	study	
visits.	Describe	the	associations	of	clinical	outcomes	with	maternal	and	infant	
characteristics		
5.	Study	the	efects	of	TDF/3TC	in	hepatitis	B	virus	co-infected	patients	through	annual	
serological	sampling	
6.	Evaluate	the	safety	of	ART	within	the	Option	B	Plus	strategy,	including	rates	of	drug	
toxicities	(which	wil	include	an	annual	blood	sample	for	creatinine	and	a	urine	sample),	
ARV	regimen	changes,	and	occurrence	of	birth	defects	through	interviews	at	quarterly	
study	visits	
7.	Evaluate	subsequent	pregnancies,	including	the	incidence	and	interval	of	recurrent	
pregnancies,	ANC	service	uptake	in	recurrent	pregnancies,	pregnancy	outcomes	and	
early	HIV-transmission		
8.	Describe	resistance	patterns	among	women	with	HIV-1	RNA	>400	copies/ml	and	
study	factors	associated	with	drug	resistance	
9.	Describe	the	preferences,	uptake	and	use	of	family	planning	after	the	incident	birth.		
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Expected	Outcomes:	
1.	Survival	rates	of	mothers	and	infants	at	36	and	48	months,	determined	by	Kaplan-
Meier	survival	analysis	and	assessment	of	risk	factors	for	mortality	determined	by	Cox	
regression	analysis.	
2.	Rates	of	defaulting,	transfers	to	other	clinic	and	stop	ART	determined	by	Kaplan-
Meier	survival	analysis	and	assessment	of	risk	factors	for	defaulting	determined	by	Cox	
regression	analysis.	
3.	Rates	of	non-adherence	as	measured	by	pil	counts,	self-report,	missed/delayed	clinic	
visits	and	HIV-1RNA	and	rate	of	virological	failure	determined	by	Kaplan-Meier	survival	
analysis	and	assessment	of	risk	factors	for	non-adherence	and	virological	failure	
determined	by	Cox	regression	analysis.	Description	of	resistance	patterns	in	those	with	
virological	failure.	
4.	Description	of	health	status	(self-reported	and	functional),	morbidities,	
hospitalizations,	growth	of	infants,	side	efects	(including	lipdystrophy,	renal	function	
and	cardiovascular	profile),	HCV	prevalence,	HBV	prevalence	and	HBV	treatment	
outcomes	in	those	infected,	utilization	of	family	planning	and	recurrent	pregnancies	and	
outcomes	thereof.	
	
Methods:		
Please	note	for	ful	methods	see	main	body	of	the	research	protocol.		The	folowing	
description	pertains	only	to	the	additional	procedures	for	the	48	month	cohort.		
	
Sample	size		
The	sample	size	of	the	subset	of	the	mother-infant	pair	cohort	that	wil	be	folowed	for	
48	months	is	based	on	the	viral	suppression	rate	amongst	mothers	of	enroled	infants.	
Given	that	no	data	exist	for	viral	suppression	rates	at	48	months	in	similar	
circumstances,	we	chose	50%	based	on	estimated	annual	losses	of	viral	suppression	of	
5-10%	and	similar	percentages	of	losses	to	folow	up.	Using	Open-Epi	Exact	Confidence	
Intervals	for	a	proportion	with	the	same	requirements	as	stated	in	the	sample	size	
calculation	for	the	general	cohort,	we	estimate	that	1,324	mothers	wil	need	to	be	
enroled	into	the	extended	folow-up	study	cohort	to	arrive	at	a	national	estimate	of	
viral	suppression	with	5%	precision	and	a	95%	confidence	interval.		
A	smaler	subset	of	500	mother-child	dyads	wil	be	selected	from	the	above	cohort	for	
quarterly	enhanced	folow	up.	This	wil	alow	estimation	of	the	occurrence	of	adverse	
outcomes	(a	composite	of	side	efects	and	morbidities,	expected	to	be	around	30%	
annualy)	with	5%	precision	and	a	95%	confidence	interval.	
	
Site	selection	
We	selected	13	sites	by	PPS	from	the	4	geographical	strata.	Each	site	was	among	the	
selected	sites	for	the	general	study,	had	to	have	a	comparable	expected	number	of	
exposed	infants	and	the	expected	number	of	exposed	infants	of	the	13	sites	had	to	be	
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large	enough	to	make	up	the	required	sample	size	of	1,324.	For	the	subset	of	500	
women	to	be	enroled	in	enhanced	folowup	(quarterly	visits),	five	sites	from	across	al	
geographical	strata	have	been	selected	purposefuly	from	the	13	sites	described	above.		
	
Study	Procedures	
Al	main	study	procedures	have	been	outlined	in	the	main	body	of	this	study.	See	
Methods	Section.	This	includes	data	management,	ethical	issues	(including	specific	
consenting	procedures	for	enrolment	and	folow-up	within	this	48-month	extended	
cohort).	See	Appendices	for	study	consent	forms.		
	
Data	colection	
	
In	this	subset,	the	folowing	data	wil	be	colected	in	addition	to	the	main	study	data	
colection	procedures:		
	
I.	Al	1,324	mother-child	pairs	wil	have	annual	study	visits	from	enrolment	to	48	
months	that	wil	include	the	folowing:		
• For	al	mothers:	
o Determination	of	survival,	standardized	ART	outcomes	and	routine	adherence	
data	from	ART	master	cards		
o Administration	of	an	annual	questionnaire	(See	appendices	“Annual	
Questionnaire	Form”	which	is	the	same	as	per	the	main	cohort)	
o Administration	of	an	annual	measures	form	which	includes	weight,	height,	hip	to	
waist	ratio	and	blood	pressure	(See	appendices	“Annual	Measures	Form”)	
o Annual	blood	sampling	for	HIV-1	RNA	
§ In	those	with	HIV-1	RNA	>400,	genotypic	resistance	assays	wil	be	done		
o Annual	CD4		
o Baseline	Hep	B	and	C	screening	
§ In	those	who	are	hepatitis	B	infected	at	baseline	(expected	5-10%),	HBV-
DNA,	HBeAg	and	HBsAg	wil	be	determined	annualy	from	the	same	sample	as	the	HIV-1	
RNA	
o Annual	lipid	and	blood	glucose	monitoring	for	cardiovascular	risk	monitoring	
	
• For	al	infants	in	the	study	
o Determination	of	survival,	standardized	ART	outcomes	and	routine	adherence	
data	from	ART	master	cards		
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o A	subsection	of	the	annual	interview	form	is	dedicated	to	infant	outcomes	(see	
Appendices	“Annual	Questionnaire”)		
o Administration	of	an	annual	measures	form	which	includes	weight,	height	and	
MUAC		
o Annual	HIV	testing	as	per	protocol	(see	main	study)	until	cessation	of	
breastfeeding	and/or	documented	seroconversion	
I.	In	a	subset	of	500	mothers-infant	pairs,	in	addition	to	the	above	annual	
procedures	al	dyads	wil	have	additional	quarterly	visits	including:		
• For	al	mothers:	
o Determination	of	survival,	standardized	ART	outcomes	and	routine	adherence	
data	from	ART	master	cards		
o A	quarterly	administered	questionnaire	that	wil	obtain	information	about	
intercurrent	morbidities	(including	tuberculosis	and	WHO	stage	II	and	IV	conditions),	
hospitalizations,	recurrent	pregnancies	and	outcomes,	and	the	use	of	family	planning	
(See	Appendices	48month	extended	cohort	questionnaire)	
o A	quarterly	clinical	symptoms	screen	questionnaire	for	side	efects,	co-
morbidities	and	adverse	outcomes		
o An	annual	lipodystrophy	screening	(see	Appendices	“Lipodystrophy	Screen”).		
o Annual	blood	sample	for	creatinine	and	annual	urine	sample		
• For	al	infants:	
o Determination	of	survival,	standardized	ART	outcomes	and	routine	adherence	
data	from	ART	master	cards		
o A	sub-section	of	the	quarterly	interview	form	is	dedicated	to	infant	health	status	
and	clinical	outcomes		
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Additional	appendices	available	upon	request:		
• ANC	Register	(MOH)	
• ART	Register	(MOH)	
• Adult	ART	Card	(MOH)	
• Pediatric	ART	Card	(MOH)	
• HIV-Exposed	Infant	Folow-up	Card	(MOH)	
• ART	Quarterly	Reporting	Forms	(MOH)	
• Study	Cohort	Register		
• Testing	logbook	
• 48-month	Folow-up	Register	
• Site	Supervision	Form	
• Community	Tracer	logbook	
• Community	Tracing	Form	
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Curriculum	Vitae	
	
ANNA	K.	RADIN	(GIESELMAN)	
annakradin@gmail.com	·	507/301-8003	·	4307	Tuckerman	Street	·	University	Park,	MD	20782	
	
	
EDUCATION	
	
Doctor	of	Public	Health	(DrPH)	(expected	2017)	
Johns	Hopkins	Bloomberg	School	of	Public	Health,	Baltimore,	MD	
Epidemiology	
Completed	al	PhD	coursework	and	training	in	Epidemiology	in	addition	to	DrPH	requirements	
	
Masters	of	Public	Health	(MPH),	2010		
University	of	North	Carolina;	Chapel	Hil,	NC	
Health	Behavior	&	Health	Education	
Certificate	in	International	Development	
	
Bachelor	of	Arts	(BA),	2006	
St.	Olaf	Colege;	Northfield,	MN	
History,	Spanish,	French	
Graduated	Magna	cum	laude	
	
	
EXPERIENCE	
	
Senior	Epidemiologist	and	Lead	for	Data	Use	&	Impact,	US	President’s	Emergency	Plan	for	
AIDS	Relief	(PEPFAR)	/	Ofice	of	the	Global	AIDS	Coordinator	(OGAC),	State	Department;	
Washington,	DC	(Oct	2016	–	present)	
- Serve	as	lead	for	data	use	and	impact	in	PEPFAR,	directly	supervising	team	of	five	
strategic	information	advisors	(epidemiologists)	
- Lead	development	of	targets	for	PEPFAR’s	fiscal	year	2017	country	operational	plan	
(COP)	cycle	for	37	countries	at	the	national,	sub-national,	implementing	partner,	and	
facility-levels.	Includes	development	of	methodology	for	target-setting	and	
development	of	database-	and	Excel-based	tools	to	assist	country	teams	in	consultation	
with	epidemiologists	and	data	experts	from	the	Centers	for	Disease	Control	&	
Prevention	(CDC),	the	US	Agency	for	International	Development	(USAID),	the	
Department	of	Defense	(DOD),	and	other	U.S.	Government	Federal	Agencies.	
- Serve	as	strategic	information	advisor	and	primary	liaison	between	the	Ofice	of	the	
Global	AIDS	Coordinator	(OGAC)	and	Mozambique	&	Côte	d’Ivoire	country	programs	for	
al	data	and	epidemiology-related	program	issues	
- Develop	PEPFAR	guidance	on	data	colection,	indicator	definitions,	data	analysis,	and	
use;	regularly	contribute	to	design	of	data	visualizations	for	internal	and	external	
PEPFAR	websites	
- Lead	development	of	al	major	presentations	for	U.S.	Global	AIDS	Coordinator	(2-4	
presentations/week)	for	scientific	and	non-scientific	audiences.	
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Senior	Advisor,	US	President’s	Emergency	Plan	for	AIDS	Relief	(PEPFAR)	/	Ofice	of	the	Global	
AIDS	Coordinator,	State	Department;	Washington,	DC	
Detailed	from	the	Centers	for	Disease	Control	&	Prevention	(CDC)	to	State	Department	(Aug	2014	
–	Oct	2016)	
- Served	as	senior	advisor	for	epidemiology,	data	analysis,	and	data	visualization,	for	the	
U.S.	Global	AIDS	Coordinator	and	U.S.	Special	Representative	for	Global	Health	
Diplomacy,	who	oversees	the	U.S.	President's	Emergency	Plan	for	AIDS	Relief	(PEPFAR)	
and	the	U.S.	contribution	to	the	Global	Fund	for	AIDS,	Tuberculosis,	and	Malaria,	with	a	
total	annual	budget	of	$6.8	bilion	in	fiscal	year	2016.	
- Continuously	reviewed	PEPFAR	program	data	and	independently	conducting	
epidemiological	analyses	to	inform	PEPFAR	programmatic	direction	and	policy	
priorities.	
- Provided	scientific	leadership	on	PEPFAR	technical	guidance	and	strategy	documents	
- Led	development	of	al	major	presentations	for	the	U.S.	Global	AIDS	Coordinator	(2-4	
presentations/week)	for	scientific	and	non-scientific	audiences	
	
Senior	Advisor	for	Prevention	of	Mother-To-Child	Transmission	of	HIV	(PMTCT),	US	President’s	
Emergency	Plan	for	AIDS	Relief	(PEPFAR)/Ofice	of	the	Global	AIDS	Coordinator,	State	
Department;	Washington,	DC	
Detailed	from	the	Centers	for	Disease	Control	&	Prevention	(CDC)	to	State	Department	(Jul	2011-
Aug	2014)	
- Managed	PEPFAR’s	work	in	maternal	&	child	health	and	virtual	elimination	of	new	
pediatric	HIV	infections	
- Oversaw	portfolio	with	$300	milion	annual	budget	to	support	PMTCT	programs	in	27	
countries	
- Provided	technical	leadership	as	co-chair	of	PEPFAR	PMTCT	&	Pediatrics	Technical	
Working	Group	
- Represented	US	government	on	Executive	Committee	of	Inter-Agency	Task	Team	(IATT)	
on	PMTCT;	technical	colaboration	with	>30	partners	(multilateral,	bilateral,	public,	
private,	NGO,	and	civil	society)	
- Conducted	regular	technical	assistance	visits	to	support	programs	in	Sub-Saharan	Africa	
(8-12	visits/year)	
- Advised	senior	leadership	(US	Ambassadors,	Ministers	of	Health,	National	AIDS	Control	
Directors)	and	provided	technical	and	management	recommendations	for	PEPFAR	and	
national	HIV/AIDS	programs	
- Developed	and	contributed	to	presentations,	speeches,	blogs,	and	opinion	pieces	for	
senior	US	government	oficials	(including	Ambassador,	Secretary	of	State,	President)	
	
Public	Health	Analyst,	Centers	for	Disease	Control	&	Prevention	(CDC),	Global	AIDS	Program;	
Atlanta,	GA	
Senior	Program	Manager,	Ofice	of	the	Director,	Division	of	Global	HIV/AIDS	(Mar-Jul	2011)	
- Provided	direct	programmatic,	management,	and	advisory	support	to	Director	of	CDC’s	
Division	of	Global	HIV/AIDS	(DGHA),	who	oversaw	an	annual	budget	of	nearly	$2	bilion	
and	>3,000	staf	
- Developed	internal	&	external	communications	on	behalf	of	Division	Director;	drafted	
presentations	and	speeches;	represented	the	Division	in	high	level	CDC	management	
meetings	
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- Managed	high	priority	initiatives	across	the	Division	including	development	of	Country	
Management	&	Support	strategy	to	enhance	oversight	and	accountability	across	43	
country	programs	
	
Country	Oficer,	Country	Operations	Branch	(Jul	2010-Feb	2011)	
- Served	as	liaison	between	CDC	headquarters	and	field	ofices	in	six	countries	
(Afghanistan,	Cameroon,	Haiti,	Nigeria,	Pakistan,	and	[South]	Sudan);	
- Provided	technical	and	operational	support	to	country	teams	via	regular	technical	
assistance	visits	
- Managed	Division-wide	Country	Assistance	Plan	review	process	
- Coordinated	interagency	Country	Operational	Planning	process	in	Cameroon	including	
development	of	$15M	budget	
	
Sexual	&	Reproductive	Health	Capstone,	El	Pueblo;	Raleigh,	NC	/	Ipas;	Chapel	Hil,	NC	(Aug	
2009-May	2010)	
- Designed	and	conducted	evaluation	of	comprehensive	sexual	and	reproductive	health	
program	to	train	Latino	youth	in	advocacy	and	peer	education	
- Conducted	in-depth	interviews	and	focus	group	discussions	with	20	recently-trained	
Latino	youth	and	their	parents;	presented	findings	to	funders	
- Developed	300-page	evidence-based	curriculum	incorporating	evaluation	results	
	
Water	and	Environmental	Sanitation	Intern,	UNICEF;	Dhaka,	Bangladesh	(May-Jul	2009)	
- Conducted	critical	analysis	of	external	health	impact	study	of	UNICEF’s	Sanitation,	
Hygiene	Education,	and	Water	Supply	in	Bangladesh	program,	which	reaches	over	32	
milion	people	
- Developed	monitoring	and	evaluation	framework	and	conducted	site	visits	in	rural	
regions	
- Contributed	to	national	disaster	preparedness	plan;	reviewed	relief	proposals	from	
international	NGOs	after	Cyclone	Aila;	coordinated	relief	plan	with	senior	government	
oficials	
	
Graduate	Research	Assistant,	UNC	Lineberger	Cancer	Center;	Chapel	Hil,	NC	(Aug	2008-May	
2009)	
- Conducted	literature	reviews	on	disparities	in	access	to	cancer	screening	among	
minority	populations	
- Developed	IRB	proposal	and	contributed	to	qualitative	study	with	300	low-income	and	
minority	residents	regarding	access	to	cancer	screening	and	treatment	services	in	North	
Carolina	
- Designed	Capstone	project	for	MPH	students	with	United	Way	to	improve	2-1-1	hotline	
for	social	services	
	
Analyst,	Technology	and	Management	Services,	Inc.;	Washington,	DC	
U.S.	Department	of	Energy	–	Energy	Eficiency	and	Renewable	Energy	(EERE)	(Jul	2006-Jun	
2008)	
- Managed	EERE’s	clean	energy	work	with	National	Governor’s	Association;	liaised	with	
senior	state	policy	advisors	to	coordinate	federal	and	state	energy	priorities	
- Developed	metrics	to	evaluate	state	investments	in	clean	energy	
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- Synthesized	information	into	briefing	documents	and	regularly	briefed	senior	
Department	oficials	
- Drafted	speeches	and	managed	Congressional	correspondence	
	
U.S.	Bureau	of	Indian	Afairs	(Sep-Dec	2006)	
- Researched	American	Indian	education;	conducted	literature	review;	assisted	in	design	
of	evaluation	and	interview	guide	for	key	informant	interviews	and	focus	groups;	
contributed	to	final	research	report	
	
West	Africa	Intern,	American	Refugee	Committee,	International	(ARC);	Minneapolis,	MN	(Feb-
May	2006)	
- Supported	Director	of	African	Programs;	drafted	grant	proposals	for	gender-based	
violence,	reproductive	health,	HIV/AIDS,	and	microenterprise	development	projects	in	
West	Africa	
	
Oral	History	Research	&	Volunteer,	Children	Better	Way	(CBW);	Buduburam	Refugee	Camp	
(Jan	2006)	
- Awarded	competitive	Kloeck-Jensen	Grant	for	Peace	and	Social	Justice	from	St.	Olaf	
Colege	to	conduct	oral	history	research	in	Liberian	refugee	camp	in	Ghana	
- Recorded	personal	stories	of	22	refugees	regarding	Liberian	Civil	War	and	extended	
exile	in	the	Buduburam	Camp;	developed	senior	thesis	for	history	degree	based	on	this	
primary	research	
- Volunteered	with	local	community-based	organization,	Children	Better	Way:	taught	
French	classes,	assisted	in	HIV/AIDS	outreach,	developed	curriculum	for	adult	literacy	
program,	led	after	school	recreational	activities	
	
	
AWARDS	&	HONORS	
	
Extra	Mile	Award,	US	Department	of	State	
Selected	for	Department-wide	award	for	outstanding	performance	and	technical	assistance	
provided	to	the	President’s	Emergency	Plan	for	AIDS	Relief	(PEPFAR)	country	teams	in	
strategicaly	analyzing	and	using	data	to	help	achieve	HIV/AIDS	epidemic	control	(2017)	
	
HIV/AIDS	Training	Grant,	National	Institutes	of	Health	(NIH)	and	Johns	Hopkins	
University	Bloomberg	School	of	Public	Health	
Selected	for	highly	competitive	pre-doctoral	training	position	on	the	HIV	Epidemiology	and	
Prevention	Sciences	Training	Program	at	Johns	Hopkins	Bloomberg	School	of	Public	Health.	
Training	grant	includes	ful	tuition	for	doctoral	studies,	stipend,	and	support	for	research-
related	expenses	(2016-2017)	
	
Mary	B.	Meyer	Felowship,	Epidemiology	Department,	Johns	Hopkins	University	Bloomberg	
School	of	Public	Health	
Selected	for	highly	competitive	felowship	including	ful	tuition	for	doctoral	studies	and	
stipend	(2014-2016)	
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Center	for	Global	Health	(CGH)	Director’s	Medal	of	Excelence	in	Global	Health,	CDC	
Selected	for	demonstrating	exemplary	service	within	CDC’s	Center	for	Global	Health	by	
exemplifying	high	ideals,	innovation,	and	impact	in	the	context	of	global	HIV/AIDS	(2012)	
	
Commitment	Award,	US	Department	of	State,	Ofice	of	the	Global	AIDS	Coordinator,	State	
Department	
Twice	recognized	for	demonstrating	the	highest	level	of	commitment	to	public	health	
service	through	advancing	PMTCT	and	pediatric	HIV	programming	in	PEPFAR	(2012,	2013)	
	
CGH	Director’s	Hardship	&	Dificult	Circumstances	Award,	Centers	for	Disease	Control	&	
Prevention	(CDC)	
Recognized	for	working	under	very	dificult	circumstances	for	program	development	in	
South	Sudan	and	overal	support	of	CDC’s	Center	for	Global	Health	international	public	
health	programs	(2011)	
	
Complex	Humanitarian	Emergency	Training	Program,	US	Centers	for	Disease	Control	and	
Prevention	(CDC)	
Selected	for	competitive	2-year	professional	training	program;	includes	4	weeks	of	
coursework	and	mentored	field	experience	in	international	emergency	response;	co-led	first	
Knowledge,	Attitudes,	and	Practices	(KAP)	Assessment	in	Artibonite	region	of	Haiti	after	
cholera	outbreak;	trained	and	supervised	22	Haitian	enumerators;	colected	data	via	512	
household	surveys	and	7	focus	groups	(Oct	2010-2012)	
	
Presidential	Management	Felow	(PMF),	US	Federal	Government		
Selected	for	highly	competitive	US	federal	government	leadership	program;	two-year	
felowship	included	ful-time	employment	at	CDC,	160	hours	of	formal	classroom	training,	
several	rotations	within	CDC	and	to	State	Department,	and	accelerated	promotion	(Jul	2010-	
Jul	2012)	
	
Arabic	Foreign	Language	and	Area	Studies	(FLAS)	Felowship,	US	Dept.	of	Education	
Awarded	ful	tuition	and	stipend	for	second	year	of	masters	of	public	health	program	
including	support	for	continued	study	of	Arabic	language	(Aug	2009	–	May	2010)	
	
Arabic	Felow,	State	Department	National	Security	Language	Initiative;	Tunis,	Tunisia	&	
Salalah,	Oman	
Twice	awarded	highly	competitive	Critical	Language	Scholarship	for	intensive	summer	study	
of	Arabic	in	Tunisia	(Beginning	Arabic)	and	the	Sultanate	of	Oman	(Intermediate	Arabic)	
(May-Jul	2007;	Jun-Aug	2008)	
	
	
PUBLICATIONS	&	PRESENTATIONS	
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TA,	King	RL,	Kisaakye	LN,	Ogundehin	DT,	Phelps	BR,	Watts	H,	and	Weissglas	F.	Confronting	
chalenges	in	monitoring	and	evaluation:	Innovation	in	the	context	of	the	Global	Plan	
towards	the	elimination	of	new	HIV	infections	among	children	by	2015	and	keeping	their	
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